Integrated DNA Technologies oligo manufacturing service

Friday, 15 April, 2011 | Supplied by: Glycon Pty Ltd


Integrated DNA Technologies (IDT) offers a comprehensive oligo manufacturing service with rapid turnaround times. All oligos are provided deprotected, desalted, quantified using UV spectrophotometry and checked for quality using mass spectrometry as standard, to provide high quality and yield accuracy.

Oligos are available in a range of amounts, from 25 nmol up to 10 µmol with the additional option of large-scale production up to 10 g. As well as providing standard-length oligos, IDT’s chemistry expertise allows the production of high-quality, long Ultramer DNA oligos, up to 200 bp in length, making them suitable for gene construction, cloning and DNA-directed RNA interference (ddRNAi).

Oligos can be delivered in individual tubes, as well as 96 or 384 well plates, either lyophilised or resuspended in liquid, such as water or Tris-EDTA (TE) buffer. For high-throughput laboratories, IDT offers a HOTplate service, shipping larger batches of unmodified DNA oligos with next-day delivery. For smaller-scale use, individual unmodified DNA oligos between 15 and 45 bp in length can be shipped using IDT’s SameDay high-speed delivery service. Custom RNA oligos can be synthesised and shipped with a turnaround of 2-3 business days. Where a higher degree of oligo purity is required, oligos can be purified using PAGE or HPLC. In addition, it is possible to include user-specified modifications such as nucleotide phosphorylation, fluorophore incorporation or the use of modified bases (eg, 5-Bromo-deoxyuridine).

Online: www.glycon.com.au
Phone: 1300 489 122
Related Products

Lumiprobe DusQ fluorescence quenchers

Lumiprobe offers a series of DusQ fluorescence quenchers with different spectral properties and...

Enzo Life Sciences SCREEN-WELL Epigenetics library

Enzo Life Sciences' SCREEN-WELL Epigenetics library contains 43 compounds with defined...

LSBio PathPlus Cancer Antibodies

The LSBio PathPlus Cancer series of antibodies include both well-established biomarkers of cancer...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd